Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) has shared an update.
Clarity Pharmaceuticals Ltd. has announced that JPMorgan Chase & Co. and its affiliates have ceased to be substantial holders in the company as of November 19, 2025. This change involves the sale and purchase of ordinary securities by JPMorgan’s subsidiaries, impacting the company’s shareholder structure and potentially influencing its market dynamics.
The most recent analyst rating on (AU:CU6) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Average Trading Volume: 2,633,460
Technical Sentiment Signal: Sell
Current Market Cap: A$1.33B
See more data about CU6 stock on TipRanks’ Stock Analysis page.